Drug Trial Radar · NCT02117167
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Last checked: Nov 20, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
999
Actual
Start
Apr 23, 2014
Primary completion
Dec 22, 2018
Study completion Dec 2023
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC; AstraZeneca
- First posted
- Apr 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as immunotherapy with maintenance therapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
Conditions
- Non-small Cell Lung Cancer Metastatic
Interventions
AZD2014Drug
Target: m-TOR
AZD4547Drug
Target: FGFR
AZD5363Drug
Target: AKT
AZD8931Drug
Target: HER2, EGFR
SelumetinibDrug
Target: MEK
VandetanibDrug
Target : VEGF, EGFR
Standard maintenance for squamous NSCLCDrug
PemetrexedDrug
Standard maintenance for non squamous NSCLC
DurvalumabDrug
Target: PD-L1
savolitinibDrug
target : MET
OlaparibDrug
target : PARP
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival in the targeted drug arm compared to standard maintenance therapy armTime frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier Henri Duffau
Avignon, France
Centre Hospitalier Universitaire de Besancon - Hopital Jean Minjoz
Besançon, France
Hôpital Avicenne
Bobigny, France
Institut Bergonié
Bordeaux, France
Hôpital Ambroise Paré
Boulogne-Billancourt, France
Hospices Civils de Lyon- Hôpital Louis Pradel
Bron, France
Centre François Baclesse
Caen, France
CHU Caen
Caen, France
Chu de Caen - Hopital Cote de Nacre
Caen, France
Hôpital Louis Pasteur
Chartres, France
centre Jean Perrin
Clermont-Ferrand, France
CHU Clermont Ferrand - Hôpital Gabriel Montpied
Clermont-Ferrand, France
Hopitaux Civils de Colmar
Colmar, France
Centre Hopsitalier Intercommunal de Créteil
Créteil, France
Centre Georges François Leclerc
Dijon, France
CHU Grenoble
Grenoble, France
Chd Vendee
La Roche-sur-Yon, France
CH du Mans
Le Mans, France
Centre Oscar Lambret
Lille, France
CHRU de Lille
Lille, France
Centre Léon Bérard
Lyon, France
Hôpital Nord
Marseille, France
Institut Paoli Calmettes
Marseille, France
Institut de cancérologie de l'Ouest
Nantes, France
Centre Antoine Lacassagne
Nice, France
Chr Orleans
Orléans, France
AH-HP Hôpital Saint Louis
Paris, France
AP-HP Hôpital Cochin
Paris, France
AP-HP Hôpital Tenon
Paris, France
Institut Curie
Paris, France
Centre Hospitalier de Pau
Pau, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Chru Strasbourg - Nouvel Hopital Civil
Strasbourg, France
CHI de Toulon - Hôpital Sainte-Musse
Toulon, France
CHU Toulouse -Hôpital Larrey
Toulouse, France
Hôpital Bretonneau
Tours, France
Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.